What is NDC 63850-0064?

63850-0064 is the product NDC for Everolimus, Everolimus .75 mg/1 tablet, listed with the FDA by Natco Pharma Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.

Natco Pharma Limited, NDC labeler code 63850. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Everolimus?

65 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Everolimus NDC 63850-0064 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)63850-0064Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63850-0064Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63850-0064-2	6385000640263850006402	6 BLISTER PACK in 1 CARTON (63850-0064-2) / 10 TABLET in 1 BLISTER PACKMarketed from May 20, 2021
63850-0064-6	6385000640663850006406	60 TABLET in 1 BOTTLE (63850-0064-6)Marketed from May 26, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Everolimus
Generic name (nonproprietary): everolimus
Active ingredients: Everolimus — .75 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Natco Pharma LimitedNDC labeler code 63850
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205432
Marketing start: May 20, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 63850-0064_111c2e93-390f-40c6-a626-6aa45878a801SPL ID 111c2e93-390f-40c6-a626-6aa45878a801SPL set ID d44998bb-5deb-4ee7-a0a5-979fe3f49557RxCUI 977427, 977434, 977438, 2056895UNII 9HW64Q8G6GUPC 0363850006326, 0363850006234, 0363850006432, 0363850006425, 0363850006333, 0363850006227
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463850006402 followed by a unit qualifier and the quantity

Package 63850-0064-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 14, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients: Kidney Transplant : at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids. ( 1.1 ) Liver Transplant : Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids. ( 1.2 , 5.5 ) Limitations of Use: Safety and efficacy have not been established in the following: Kidney transplant patients at high immunologic risk ( 1.3 ) Recipients of transplanted organs other than kidney or liver ( 1.3 , 5.7 ) Pediatric patients (less than 18 years) ( 1.3 ) 1.1 Prophy…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 63850-0064

What is NDC 63850-0064?: 63850-0064 is the product NDC for Everolimus, Everolimus .75 mg/1 tablet, listed with the FDA by Natco Pharma Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Everolimus.
What is the active ingredient?: Everolimus.
Who is the labeler?: Natco Pharma Limited, NDC labeler code 63850. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Everolimus?: 65 other product NDCs are listed under this name. See all Everolimus NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Everolimus NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Everolimus	Everolimus .25 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-003	72319-0003-0272319-0003-60
Everolimus	Everolimus .5 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-015	72319-0015-0272319-0015-60
Everolimus	Everolimus .75 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-016	72319-0016-0272319-0016-60
Everolimus	Everolimus 1 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-017	72319-0017-0272319-0017-60
everolimus	Everolimus 7.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-032	82293-0032-1082293-0032-2182293-0032-31
everolimus	Everolimus 2.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-030	82293-0030-1082293-0030-2182293-0030-31
everolimus	Everolimus 5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-031	82293-0031-1082293-0031-2182293-0031-31
everolimus	Everolimus 10 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-033	82293-0033-1082293-0033-2182293-0033-31
everolimus	Everolimus .75 mg/1	TabletOral	Aurobindo Pharma Limited	59651-933	59651-0933-60
everolimus	Everolimus .25 mg/1	TabletOral	Aurobindo Pharma Limited	59651-931	59651-0931-60

All 66 Everolimus NDCs

Other NDCs under ANDA 205432

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205432
Product	Strength	Form · route	Labeler	Product NDC
Everolimuseverolimus tablets	Everolimus .75 mg/1	TabletOral	Breckenridge Pharmaceutical, Inc.	51991-381
Everolimuseverolimus tablets	Everolimus .25 mg/1	TabletOral	Breckenridge Pharmaceutical, Inc.	51991-379
Everolimuseverolimus tablets	Everolimus .5 mg/1	TabletOral	Breckenridge Pharmaceutical, Inc.	51991-380
Everolimus	Everolimus .5 mg/1	TabletOral	Natco Pharma Limited	63850-0063
Everolimus	Everolimus .25 mg/1	TabletOral	Natco Pharma Limited	63850-0062
Everolimus	Everolimus 1 mg/1	TabletOral	Natco Pharma Limited	63850-0107
Everolimuseverolimus tablets	Everolimus 1 mg/1	TabletOral	Breckenridge Pharmaceutical, Inc.	51991-985